Latest filing published 21 Sept 2026 for Enhanced Group Inc., €6.1M. Read the official filing
Across 9 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Apeiron Investment Group Ltd. has filed trades across 5 companies (mainly through SEC (Form 4)), most often in ATAI Life Sciences N.V., Enhanced Group Inc. and Faeth Therapeutics, Inc. Between 22 June 2021 and 17 September 2026, the trades on record add up to 31 filings.
Both buying and selling appear: 25 purchases worth €62.0M, against 2 sales worth €3.7M. On balance, insiders were net buyers of €58.3M. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Outside the open market, there are 2 share grants. Since January 2026: 11 purchases and no sales on the market.
Half of the purchases are above €249k and half below. Scaled by market value, the purchases weigh a median 0.027% of market cap (sample: 11 purchases). Clusters matter here: 1 out of 25 purchases overlapped with buying by a colleague within 30 days. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase.
Most recently, on 21 September 2026, the filings show an open-market purchase worth €6.1M in Enhanced Group Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. The legal deadline for a Form 4 is two business days after the transaction. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
25 of 31 declarations